Form D · Biotechnology
CRITICAL BIOLOGICS CORP
Cambridge, MA · CIK 0001387704
Offering snapshot reported Aug 3, 2009 · SEC filing
- Reported sold
- $500K Offering amount: $1.6M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 24, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 3, 2009 | Initial | $500,000 | No comparison | 12 | SEC filing |
| Jul 21, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 22, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 22, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-99265
Source: Form D, filed Aug 3, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gerald Chan | Director |
| Scott Coleridge | Director, Executive |
| James W. Fordyce | Director, Executive |
| Ashleigh W. Palmer | Director, Executive |
| Thomas Stossel | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Mifflin Place Suite 400
Cambridge, MA, 02138
Cambridge, MA, 02138